Security record · archived quarter
GPCR
Structure Therapeutics Inc. · Healthcare · Biotechnology
12Tracked holders
0Δ holders
15.65MShares held
$324.65MReported value
+0New positions
−0Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -1.3% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 66 | 0 | 29.19M | $1.56B | +7 | −7 |
| Q1 2026 | 68 | -4 | 35.35M | $1.72B | +6 | −10 |
| Q4 2025 | 71 | 0 | 34.16M | $2.38B | +1 | −1 |
| Q3 2025 | 15 | 0 | 15.29M | $428.25M | +1 | −1 |
| Q2 2025 | 12 | 0 | 15.65M | $324.65M | — | — |
| Q1 2025 | 10 | +2 | 10.69M | $185.13M | +2 | — |
| Q4 2024 | 8 | -1 | 12.53M | $339.72M | — | −1 |
| Q3 2024 | 8 | -3 | 13.88M | $609.35M | — | −3 |
| Q2 2024 | 11 | — | 14.51M | $569.72M | — | — |
Who holds it · Q2 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 6.88M | -11.8% | $142.60M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 2 | Wellington Management ✦ | 6.88M | -11.8% | $142.60M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 3 | Wellington Management ✦ | 6.88M | -11.8% | $142.60M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 4 | Wellington Management ✦ | 6.88M | -11.8% | $142.60M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 5 | Wellington Management ✦ | 6.88M | -11.8% | $142.60M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 6 | Wellington Management ✦ | 6.88M | -11.8% | $142.60M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 7 | Fidelity (FMR) ✦ | 4.91M | — | $101.94M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Fidelity (FMR) ✦ | 4.91M | — | $101.94M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Fidelity (FMR) ✦ | 4.91M | — | $101.94M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 4.91M | — | $101.94M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Fidelity (FMR) ✦ | 4.91M | — | $101.94M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 1.33M | +33.9% | $27.55M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 1.33M | +33.9% | $27.55M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | Millennium Management ✦ | 1.22M | +54.4% | $25.30M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 352.87K | -54.6% | $7.32M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Point72 Asset Management ✦ | 330.00K | +43.8% | $6.84M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 17 | BlackRock ✦ (passive) | 243.33K | — | $5.05M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | BlackRock ✦ (passive) | 243.33K | — | $5.05M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | BlackRock ✦ (passive) | 243.33K | — | $5.05M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Marshall Wace ✦ | 176.06K | +474.9% | $3.65M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 21 | Marshall Wace ✦ | 176.06K | +474.9% | $3.65M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 22 | Marshall Wace ✦ | 176.06K | +474.9% | $3.65M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 23 | Renaissance Technologies ✦ | 111.90K | +608.2% | $2.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 24 | Geode Capital Management ✦ (passive) | 54.18K | +18.5% | $1.12M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 25 | State Street Global Advisors ✦ (passive) | 33.46K | +211.5% | $693,940 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 26 | D. E. Shaw & Co. ✦ | 12.16K | +4.3% | $252,302 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 118.22K shares, $5.19M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Aug 06
SC 13G/A — FMR LLC
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2025 ·
Methodology ·
Get this via the API